Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP, CHIEF FINANCIAL OFFICER | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,677 |
Reported balance
After 2026-08-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-05 · Exercise / conversion · Acquired 5,849 · Balance 73,677 F1: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 67,828 |
Reported balance
After 2026-08-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-05 · Sale · Disposed 5,849 · Balance 67,828 F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Common StockSEC Table I · non-derivative | Direct | 82,120 |
Reported balance
After 2026-08-06 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-08-06 · Exercise / conversion · Acquired 14,292 · Balance 82,120 |
| Common StockSEC Table I · non-derivative | Direct | 77,120 |
Reported balance
After 2026-08-06 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-08-06 · Sale · Disposed 5,000 · Balance 77,120 F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 67,828 |
Reported balance
After 2026-08-06 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-08-06 · Sale · Disposed 9,292 · Balance 67,828 F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.84 · Expires 2034-03-24 | Direct | 74,715 |
Reported balance
After 2026-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-05 · Exercise / conversion · Disposed 5,849 · Balance 74,715 F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.84 · Expires 2034-03-24 | Direct | 60,423 |
Reported balance
After 2026-08-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-06 · Exercise / conversion · Disposed 14,292 · Balance 60,423 F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.
F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2024 Filed Aug 20, 2024 22:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 9,733 | $15.28 | $148,720.24 |
DisclosureSEC source: 0001415889-24-021731 · form4-08202024_100820.xml · nonDerivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,735 F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 13,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021731 · form4-08202024_100820.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,468 F2 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 5,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021731 · form4-08202024_100820.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,839 F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 975 | $14.79 | $14,420.25 |
DisclosureSEC source: 0001415889-24-016416 · form4-06112024_060601.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,564 F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.675 to $14.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016416 · form4-06112024_060601.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024. F5 · derivative.expiration_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024. Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-016416 · form4-06112024_060601.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 1,593 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,503 | $16.94 | $59,340.82 |
DisclosureSEC source: 0001415889-24-012237 · form4-05032024_060510.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,053 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.94 to $17.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012237 · form4-05032024_060510.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,445 Underlying: Common Stock · 6,814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,814 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-012237 · form4-05032024_060510.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 08, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,716 | $17.87 | $48,534.92 |
DisclosureSEC source: 0001415889-24-010601 · form4-04092024_060401.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,742 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.7338 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010601 · form4-04092024_060401.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,551 Underlying: Common Stock · 5,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010601 · form4-04092024_060401.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 27, 2024 Filed Mar 27, 2024 23:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 5,434 | $17.90 | $97,268.60 |
DisclosureSEC source: 0001415889-24-009270 · form4-03272024_110354.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,183 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 23:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 24,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009270 · form4-03272024_110354.xml · derivative · entry 4 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,714 Underlying: Common Stock · 24,714 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 23:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 80,564 | $0.00 Strike: $17.84 | $0.00 |
DisclosureSEC source: 0001415889-24-009270 · form4-03272024_110354.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,564 Underlying: Common Stock · 80,564 shares Expires 2034-03-24 F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 23:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 10,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009270 · form4-03272024_110354.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,617 F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 23:13 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 772 | $24.67 | $19,045.24 |
DisclosureSEC source: 0001415889-24-005577 · form4-02272024_110237.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,067 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:13 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005577 · form4-02272024_110237.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,353 Underlying: Common Stock · 1,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:13 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-005577 · form4-02272024_110237.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 5,108 | $22.64 | $115,645.12 |
DisclosureSEC source: 0001209191-23-056357 · doc4.xml · nonDerivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,486 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.5753 to $22.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 4,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056357 · doc4.xml · derivative · entry 5 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,826 Underlying: Common Stock · 4,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 4,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056357 · doc4.xml · derivative · entry 4 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,826 Underlying: Common Stock · 4,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,956 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056357 · doc4.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,956 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056357 · doc4.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 23:31 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 10,000 | $29.00 | $289,970.00 |
DisclosureSEC source: 0001209191-23-047125 · doc4.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,682 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 to $29.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 1,593 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2023. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 00:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036529 · doc4.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,893 Underlying: Common Stock · 1,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 00:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 974 | $25.02 | $24,369.48 |
DisclosureSEC source: 0001209191-23-036529 · doc4.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,824 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 00:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036529 · doc4.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 14,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031243 · doc4.xml · derivative · entry 5 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,782 Underlying: Common Stock · 14,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 14,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031243 · doc4.xml · derivative · entry 4 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,782 Underlying: Common Stock · 14,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 15,310 | $22.50 | $344,475.00 |
DisclosureSEC source: 0001209191-23-031243 · doc4.xml · nonDerivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,905 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 14,869 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031243 · doc4.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 14,869 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031243 · doc4.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 27,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027205 · doc4.xml · derivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,259 Underlying: Common Stock · 27,259 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 89,936 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-23-027205 · doc4.xml · derivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,936 Underlying: Common Stock · 89,936 shares Expires 2033-05-01 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| April 06, 2023 Filed Apr 8, 2023 00:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,916 | $18.16 | $34,794.56 |
DisclosureSEC source: 0001209191-23-023863 · doc4.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,477 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 05, 2023 Filed Apr 8, 2023 00:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023863 · doc4.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,826 Underlying: Common Stock · 5,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2023 Filed Apr 8, 2023 00:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-023863 · doc4.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 577 | $18.78 | $10,836.06 |
DisclosureSEC source: 0001209191-23-013470 · doc4.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,118 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013470 · doc4.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,706 Underlying: Common Stock · 1,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-013470 · doc4.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 09, 2022 Filed Jun 11, 2022 00:51 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 653 | $17.91 | $11,694.90 |
DisclosureSEC source: 0001209191-22-036176 · doc4.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,342 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.91 to $18.449, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 00:51 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036176 · doc4.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,786 Underlying: Common Stock · 1,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024. F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 00:51 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036176 · doc4.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:49 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 21,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023741 · doc4.xml · derivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,101 Underlying: Common Stock · 21,101 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:49 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 72,414 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0001209191-22-023741 · doc4.xml · derivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,414 Underlying: Common Stock · 72,414 shares Expires 2032-04-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:43 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013281 · doc4.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,059 Underlying: Common Stock · 1,352 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:43 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 553 | $23.80 | $13,161.40 |
DisclosureSEC source: 0001209191-22-013281 · doc4.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,102 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:43 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013281 · doc4.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.